An Evaluation of the Role of Properdin in Alternative Pathway Activation on Neisseria meningitidis and Neisseria gonorrhoeae
Properdin, a positive regulator of the alternative pathway (AP) of complement is important in innate immune defenses against invasive neisserial infections. Recently, commercially available unfractionated properdin was shown to bind to certain biological surfaces, including Neisseria gonorrhoeae, which facilitated C3 deposition. Unfractionated properdin contains aggregates or high-order oligomers, in addition to its physiological "native" (dimeric, trimeric, and tetrameric) forms. We examined the role of properdin in AP activation on diverse strains of Neisseria meningitidis and N. gonorrhoeae specifically using native versus unfractionated properdin. C3 deposition on Neisseria decreased markedly when properdin function was blocked using an anti-properdin mAb or when properdin was depleted from serum. Maximal AP-mediated C3 deposition on Neisseriae even at high (80%) serum concentrations required properdin. Consistent with prior observations, preincubation of bacteria with unfractionated properdin, followed by the addition of properdin-depleted serum resulted in higher C3 deposition than when bacteria were incubated with properdin-depleted serum alone. Unexpectedly, none of 10 Neisserial strains tested bound native properdin. Consistent with its inability to bind to Neisseriae, preincubating bacteria with native properdin followed by the addition of properdin-depleted serum did not cause detectable increases in C3 deposition. However, reconstituting properdin-depleted serum with native properdin a priori enhanced C3 deposition on all strains of Neisseria tested. In conclusion, the physiological forms of properdin do not bind directly to either N. meningitidis or N. gonorrhoeae but play a crucial role in augmenting AP-dependent C3 deposition on the bacteria through the "conventional" mechanism of stabilizing AP C3 convertases.
The Journal of Immunology
An Evaluation of the Role of Properdin in Alternative
Pathway Activation on Neisseria meningitidis and
Viviana P. Ferreira,
Michael K. Pangburn,
Peter A. Rice,* and Sanjay Ram*
Properdin, a positive regulator of the alternative pathway (AP) of complement is important in innate immune defenses against in-
vasive Neisserial infections. Recently, commercially available unfractionated properdin was shown to bind to certain biological sur-
faces, including Neisseria gonorrhoeae, which facilitated C3 deposition. Unfractionated properdin contains aggregates or high-order
oligomers, in addition to its physiological “native” (dimeric, trimeric, and tetrameric) forms. We examined the role of properdin in
AP activation on diverse strains of Neisseria meningitidis and N. gonorrhoeae speciﬁcally using native versus unfractionated pro-
perdin. C3 deposition on Neisseria decreased markedly when properdin function was blocked using an anti-properdin mAb or when
properdin was depleted from serum. Maximal AP-mediated C3 deposition on Neisseriae even at high (80%) serum concentrations
required properdin. Consistent with prior observations, preincubation of bacteria with unfractionated properdin, followed by the
addition of properdin-depleted serum resulted in higher C3 deposition than when bacteria were incubated with properdin-depleted
serum alone. Unexpectedly, none of 10 Neisserial strains tested bound native properdin. Consistent with its inability to bind to
Neisseriae, preincubating bacteria with native properdin followed by the addition of properdin-depleted serum did not cause
detectable increases in C3 deposition. However, reconstituting properdin-depleted serum with native properdin a priori enhanced
C3 deposition on all strains of Neisseria tested. In conclusion, the physiological forms of properdin do not bind directly to either
N. meningitidis or N. gonorrhoeae but play a crucial role in augmenting AP-dependent C3 deposition on the bacteria through the
“conventional” mechanism of stabilizing AP C3 convertases. The Journal of Immunology, 2010, 185: 507–516.
roperdin is the only known positive regulator of the com-
plement system. Each properdin monomer is a 53 kDa
molecule. In plasma, properdin exists as cyclic dimers (P
), and tetramers (P
) formed by head-to-tail association
of monomers (1–3). The AP C3 convertase, C3b,Bb, has a t
only 1.5 min. Properdin carries out the important function of bind-
ing to and stabilizing the C3b,Bb complex, thereby increasing its
half life 5- to 10-fold (4).
When properdin was ﬁrst discovered more than 50 y ago, it was
thought to be an initiator of the alternative pathway (AP) (5). This
original theory was later changed in favor of the more widely ac-
cepted role of properdin, that of stabilizing the AP C3 convertase.
Recent studies have shown that properdin can bind directly to
AP activator surfaces, such as zymosan and rabbit erythrocytes (6),
and serve to initiate the AP by forming a platform for assembly
of AP C3 convertases (6, 7). Of note, Spitzer et al. (6) reported
that properdin bound to a strain of Neisseria gonorrhoeae and
a “rough” LPS mutant of Escherichia coli K12, and that bacteria-
bound properdin was capable of enhancing C3 deposition on these
bacteria after the addition of properdin-deﬁcient serum. These data
have important implications because properdin deﬁciency in
humans is associated with an increased incidence of invasive in-
fections with Neisseria meningitidis (8–20). The ﬁnding that pro-
perdin binds to N. gonorrhoeae and activates complement has been
extrapolated to N. meningitidis (21, 22). This newly proposed
(or perhaps more appropriately, rediscovered) mechanism provided
an attractive theory to explain why properdin-deﬁcient individuals
are exclusively predisposed to meningococcal disease (21, 22).
We questioned the ability of Neisseriae to bind to properdin
under physiological conditions for the following reasons. First,
both N. meningitidis and N. gonorrhoeae have evolved several
intricate mechanisms to evade killing by human complement (23–
34); binding of properdin by bacteria would place these pathogens
at a distinct disadvantage for survival in their human host. Second,
the study of properdin binding to N. gonorrhoeae used commer-
cially available properdin that has undergone freeze-thawing and
contains high-order oligomers, or aggregates of properdin (2, 35).
These aggregates are also called “activated” properdin or P
Unlike the physiological forms of properdin, “activated” proper-
din can promote complement activation and consumption when
added to serum (35). In addition, aggregates are also likely to bind
with higher avidity, or perhaps nonspeciﬁcally, to surfaces that
native forms of properdin may not.
In this study, we have evaluated the role of native properdin in
activating the AP on N. meningitidis and N. gonorrhoeae and have
*Division of Infectious Diseases and Immunology, University of Massachusetts Med-
ical School, Worcester, MA 01605;
Department of Medical Microbiology and Im-
munology, University of Toledo College of Medicine, Toledo, OH 43614; and
Department of Biochemistry, Center for Biomedical Research, University of Texas
Health Science Center, Tyler, TX 75708
S.A. and V.P.F. contributed equally to this work.
Received for publication November 6, 2009. Accepted for publication April 29, 2010.
This work was supported by National Institutes of Health Grants AI054544 (to S.R.),
AI32725, AI08404 8 (to P.A.R), and DK-35081 (to M.K.P.), and American Heart
Association National Scientist Development Grant 0735101N (to V.P.F.).
Address correspondence and reprint requests to Dr. Sanjay Ram, Division of Infec-
tious Diseases and Immunology, University of Massachusetts Medical School, Lazare
Research Building, Room 322, 364 Plantation Street, Worcester, MA 01605. E-mail
Abbreviations us ed in this paper: AP, alternative pathway; CMP-NANA, 59-
cytidinemonophospho-N-acetylneuraminic acid; DGI, disseminated gonococcal in-
fection; Glc, glucose; Hep, heptose; lgt, LOS glycosyl transferase; LOS, lipooligo-
saccharide; MFI, median ﬂuorescence intensity; NHS, normal human serum; P,
Copyright Ó 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00
contrasted this with unfractionated properdin. These studies pro-
vide important mechanistic insights into the role of properdin in
complement activation on the pathogenic Neisseriae.
Materials and Methods
One representative strain from each of the ﬁve major meningococcal
serogroups that cause disease worldwide (A, B, C, W-135, and Y) and their
isogenic unencapsulated mutants were used in this study. With rare excep-
tions (36, 37), almost all meningococci isolated from the blood or cere-
brospinal ﬂuid are encapsulated (38). Isogenic unencapsulated mutants
were also studied because strains carried in the nasopharynx often do
not express capsules (39) and further, invasive isolates must downregulate
capsule production while traversing epithelial barriers (40, 41). To mini-
mize regulation of the AP by sialylation of lipooligosaccharide (LOS)
[reviewed in Ref. 32], the LOS sialyltransferase gene (lst) of serogroups
B, C, W-135, and Y strains was abrogated by insertional inactivation (lst::
), as described previously (42). Serogroup A N. meningitidis do not
synthesize 59-cytidinemonophospho-N-acetylneuraminic acid (CMP-
NANA), the donor molecule for LOS sialylation, and therefore can sialy-
late its LOS only when CMP-NANA is added to growth media. Five strains
of N. gonorrhoeae that differed in their PorB type, sensitivity to the
bactericidal action of normal human serum and the clinical syndrome they
caused were used in this study. In addition, LOS mutations of one of the
strains, F62, was used to examine the role of LOS truncation on interaction
of this strain with properdin. Insertional inactivation of LOS glycosyl
transferase, lgtE and lgtF, of F62 using methods described previously
(43) yielded isogenic mutant strains that expressed truncated LOS mole-
cules (lgtE mutant, glucose [Glc]→heptose [Hep]I; lgtF mutant, HepI
unsubstituted). Sialylation of F62 gonococcal LOS was achieved by adding
CMP-NANA to the growth media to a ﬁnal concentration of 1 mg/ml. All
Neisserial strains were routinely cultured on chocolate agar plates at 37˚C
in the presence of 5% CO
. Strains and their relevant characteristics are
listed in Table I.
Sera, C3, Abs, and zymosan
Properdin-depleted serum (P-depleted serum) was purchased from Quidel
(Santa Clara, CA) (catalog no. A512). Serum depleted of C3 by immu-
noafﬁnity chromatography was purchased from Complement Technology
Tyler, TX) (catalog no. A314). C3 was puriﬁed from human plasma by
PEG precipitation and DEAE Sephacel chromatography as described pre-
viously (44). Two anti-properdin mAbs were purchased from Quidel (cat-
alog nos. A233 and A235). MAb A233 blocks properdin function;
whereas, mAb A235 binds to properdin but does not block the function
of properdin. C3 deposition on bacteria and zymosan was detected by anti-
FIGURE 1. Binding of properdin (P) to Neisseriae after incubation with commercially available unfractionated puriﬁed human P (10 mg/ml). A, Five
encapsulated strains of N. meningitidis (one representative strain from each of the ﬁve major serogroups A, B, C, W-135, and Y) and their isogenic
unencapsulated mutants. Bacteria-bound P was detected by ﬂow cytometry using an anti-properdin mAb (Quidel; catalog no. A235) followed by anti-mouse
IgG conjugated to Alexaﬂuor 647. In all graphs, the x-axis represents ﬂuorescence on a log
scale and the y-axis the number of events. Controls, where P
was omitted from the reaction mixture, are shown by the broken line histograms. Numbers adjacent to the histograms represent median ﬂuorescence
intensities (MFIs) of P binding; numbers in the box with the dashed border represents ﬂuorescence of the control bacteria, numbers in the gray shaded
box binding to encapsulated bacteria and the box with a solid black outline binding to unencapsulated meningococci. B, P binding to ﬁve strains of
N. gonorrhoeae and (C) properdin binding to zymosan. One experiment of two reproducibly repeated experiments is shown for each of the histograms.
508 PROPERDIN IN NEISSERIAL INFECTIONS
human C3c conjugated to FITC from Biodesign (now Meridian Life Science,
Saco, ME). Sera obtained fresh from 10 normal adults (normal human serum
[NHS]) were pooled and stored at –80˚C until used. All sera contained 10 mM
to permit selecti v e activation of the AP.
Puriﬁcation and fractionation of properdin
Properdin was puriﬁed from normal human plasma as described (45) and
stored at 280˚C until further fractionated. Alternatively, puriﬁed human
properdin was obtained either from Complement Technology or from
Quidel. Commercially available properdin or properdin that was puriﬁed in
the laboratory and stored at 280˚C is referred to in this study as unfrac-
tionated properdin. Pure, frozen properdin was thawed and the physio-
) forms and the aggregated P
forms were separated by
cation exchange chromatography, followed by size exclusion chromatog-
raphy (2). Brieﬂy, thawed properdin was separated using a 1 ml Mono
S cation exchange column and the recovered oligomers further separated
by gel ﬁltration on Phenomenex Bio Sep-Sec-S4000 column. The proper-
din sample, in PBS, was loaded onto a 600 3 7.8 mm molecular sieve
column and eluted at a ﬂow rate of 0.5 ml/min. Fractionated properdin was
stored at 4˚C and was used in experiments within 2 wk to minimize re-
aggregation of the properdin that can occur with prolonged storage (2).
Properdin binding and C3 deposition by ﬂow cytometry
bacteria were harvested from a 12–14 h culture on a chocolate
agar plate and suspended in HBSS containing 0.15 mM CaCl
and 1 mM
). Zymosan was also suspended in HBSS
at a concen-
tration of 3 3 10
particles/ml. Bacteria or zymosan were washed once
and 5 3 10
bacteria or zymosan particles were incubated
for 30 min at 37˚C with either: properdin (10 mg/ml); NHS-Mg/EGTA;
C3-depleted serum-Mg/EGTA; properdin-depleted serum-Mg/EGTA; or
C3-depleted serum-Mg/EGTA reconstituted with puriﬁed C3 (1 mg/ml),
each used in a ﬁnal reaction volume of 100 ml; the ﬁnal concentration of
sera in these experiments was 20%. Properdin that bound to bacteria or
zymosan was detected using anti-human properdin mAb (Quidel catalog
no. A235) at a dilution of 1:100, followed by anti-mouse IgG conjugated to
Alexaﬂuor 647 (1:400). Data were collected either on a LSR II ﬂow
cytometer (Becton Dickinson, Franklin Lakes, NJ) or a FACSCalibur in-
strument (Becton Dickinson) and analyzed using the FlowJo analysis soft-
ware program (Version 7.2.4, TreeStar, Ashland, OR).
The functional importance of properdin in mediating AP-dependent C3
deposition (includes both the C3b and iC3b fragments) on Neisseria was
assessed by two methods: 1) the function of properdin was blocked with an
anti-properdin mAb, and 2) C3 deposited on bacteria by properdin-depleted
serum was compared with C3 deposited by properdin-depleted serum
reconstituted with puriﬁed properdin. The concentration of properdin in
reconstituted sera was 10 mg/ml. All reaction mixtures contained 10 mM
and 10 mM EGTA to inhibit classical and lectin pathway activation
(both dependent on Ca
) and restrict complement activation to the Mg
dependent AP. In the ﬁrst method, properdin function in serum was blocked
by adding anti-properdin mAb (Quidel catalog no. A233) to Mg/EGTA-
NHS to a ﬁnal concentration of 50 mg/ml. Total C3 deposition on bacteria
was detected after incubation of bacteria with Mg/EGTA-NHS (20% v/v)
containing the anti-properdin mAb in a ﬁnal volume of 100 ml. Bacteria
incubated with Mg/EGTA-NHS (no anti-properdin mAb added) served as
a control. Reaction mixtures were incubated for 30 min at 37˚C and total C3
(C3b plus iC3b) binding to bacteria was detected by ﬂow cytometry using
anti-C3c FITC as described previously (26, 28). In the second method, C3
deposition on bacteria incubated with properdin-depleted serum was com-
pared with C3 deposition using properdin-depleted serum that was recon-
stituted either with unfractionated properdin or with properdin fractions
(described previously), each to a concentration of 10 mg/ml.
To determine whether preincubation of bacteria with properdin would
enhance C3 deposition, bacteria were incubated with puriﬁed unfractionated
properdin or properdin fractions (10 mg/ml in a ﬁnal volume of 100 ml) for
20 min at 37˚C, washed once to remove unbound properdin, followed by
the addition of P-depleted serum to a ﬁnal concentration 20% [v/v]). As
a comparator, we measured C3 deposition on bacteria that were incubated
with properdin-depleted serum reconstituted with the corresponding pro-
perdin form to a ﬁnal concentration of 10 mg/ml; this reconstituted serum
was added to the bacteria to achieve a ﬁnal serum concentration of 20%
(v/v) in the reaction mixture. Baseline C3 deposition independent of pro-
perdin function was measured by incubating bacteria with properdin-
depleted serum. Total C3 (C3b plus iC3b) deposited on bacteria was
detected using anti-human C3c conjugated to FITC (1:100 dilution in
/1% BSA) as described previously (26, 28).
Binding of unfractionated puriﬁed properdin to Neisseriae
We quantiﬁed the bindingofunfractionatedpuriﬁedproperdintoﬁve
meningococcal strains and their isogenic unencapsulated mutants
and also to ﬁve strains of N. gonorrhoeae. Zymosan has been shown
previously to bind to puriﬁed properdin directly by ﬂow cytometry
(6) and was used as a positive control. Only minimal binding of
unfractionated puriﬁed properdin to unencapsulated meningococcal
subpopulations of serogroups A, C, and W-135 strains was seen
relative to controls; capsule expression further decreased properdin
binding to these serogroups (Fig. 1A). Gonococcal strains bound
varying amounts of puriﬁed properdin; the highest levels of pro-
perdin binding were observed with N. gonorrhoeae F62; whereas,
minimal binding was seen with strains WG and 24-1 (Fig. 1B).
No correlation was apparent between the ability of a gonococcal
Table I. Bacterial strains used in this study
Strain Relevant Characteristics Reference
A2594 A:4:P1.9:ST-5; Germany, 1991; encapsulated; LOS not sialylated (25)
A2594 mynB Insertional inactivation of mynB (mynB:: Cm
) of A2594; unencapsulated,
LOS not sialylated
H44/76 lst Insertional inactivation of lst of H44/76 (B:15:P1.7,16: ST-32; Norway, 1976); (lst::Km
encapsulated, LOS not sialylated
H44/76 siaD lst Insertional inactivation of siaD of H44/76 lst (siaD::Cm
LOS not sialylated
C2120 lst Insertional inactivation of lst of strain C2120 (C:NT:P1.5,2:ST-11; Germany, 1997)
); encapsulated, LOS not sialylated
C2120 siaD lst Insertional inactivation of siaD of strain C2120 lst (siaD::Cm
); unencapsulated, LOS not sialylated (25)
W171 lst Insertional inactivation of lst of W171 (W135:NT:P1.10:ST-11) (lst::Km
); encapsulated, LOS not sialylated This study
W171 siaD lst Insertional inactivation of siaD of W171 lst (siaD::Cm
); unencapsulated, LOS not sialylated (25)
Y2220 lst Insertional inactivation of lst of Y2220 (Y:21:P1.15:ST-172) (lst::Km
); encapsulated, LOS not sialylated This study
Y2220 siaD lst Insertional inactivation of lst of Y2220 siaD (lst::Km
); unencapsulated, LOS not sialylated (25)
F62 PorB.1B, serum sensitive (53)
24-1 PorB.1B, serum sensitive (54)
398079 PorB.1B, serum sensitive (55)
WG PorB.1B, serum resistant (DGI isolate) (56)
15253 PorB.1A, serum resistant (DGI isolate) (48)
F62 lgtE F62 lgtE::kan; Glc→HepI This study
F62 lgtF F62 lgtF::spc; HepI unsubstituted This study
DGI, disseminated gonococcal infection.
The Journal of Immunology 509
strain to resist complement-dependent killing (Table I) and the
amount of properdin binding (Fig. 1B). Furthermore, sialylation
of the LOS of N. gonorrhoeae F62 by growth in media containing
CMP-NANA did not affect properdin binding (data not shown).
As expected, zymosan bound unfractionated properdin well
Properdin plays a critical role in AP-mediated C3 deposition
on meningococci and gonococci
The functional importance of properdin in mediating AP-dependent
C3 deposition on N. meningitidis and N. gonorrhoeae was assessed
by two methods: 1) use of an anti-properdin mAb to block the
function of properdin present in serum, and 2) use of properdin-
Meningococcal and gonococcal strains described in Fig. 1 were
used in the following experiments. First, the function of properdin
in AP-mediated C3 deposition on Neisseriae was evaluated by
using a mAb that blocks properdin function (50 mg mAb
A233/ml serum). Shown in Fig. 2A, C3 deposition on both encap-
sulated (upper panel, all except serogroup C) and unencapsulated
(lower panel, all) meningococcal strains decreased markedly
when properdin function was blocked with the anti-properdin
mAb. These data point to a central role for properdin in enhancing
AP activation on meningococci. This observation was conﬁrmed
by using properdin-depleted Mg/EGTA-treated human serum,
shown in Fig. 2B, where minimal deposition of C3 occurred as
a result of marked diminution of AP activation in properdin-
depleted serum; reconstitution of depleted serum with physiologic
concentrations of unfractionated properdin increased C3 binding
to all strains, except encapsulated serogroup C and W-135 isolates.
These studies were performed with unfractionated properdin to
simulate prior observations made by Spitzer et al. (6).
Similarly, the importance of properdin in promoting AP activation
on N. gonorrhoeae was demonstrated. A 4- to 10-fold decrease in C3
deposition (ﬂuorescence) on all ﬁve strains occurred when properdin
function was blocked with anti-properdin mAb (Fig. 3A). Incubation
FIGURE 2. P augments AP-mediated C3 deposition on N. meningitidis. A, Five encapsulated strains of N. meningitidis (upper panel) and their isogenic
unencapsulated mutants (lower panel) were incubated with NHS-Mg/EGTA (20% [v/v]) either in the absence (gray shaded histograms) or in the presence
(histograms depicted by solid lines) of an anti-properdin mAb that blocks P function (Quidel; catalog no. A233). Total C3 deposited on the bacterial surface
was measured by ﬂow cytometry using sheep polyclonal anti-human C3c conjugated to FITC. B, C3 deposition was assessed on the 10 strains of
N. meningitidis on incubation with P-depleted serum-Mg/EGTA (20% [v/v]) (histograms depicted by solid lines), or with P-depleted serum-Mg/EGTA
reconstituted with puriﬁed unfractionated properdin to a concentration of 10 mg/ml (gray shaded histograms). Detection of C3 was performed as indicated
above. Axes are as described in Fig. 1. Controls (no serum added to bacteria) are shown by the broken lines. Controls with heat-inactivated serum show
nearly identical tracings and have been omitted for simplicity. Numbers adjacent to histograms represent the MFIs of C3 binding. One representative
experiment of two separately performed and reproducibly repeated experiments is shown for each of the histograms.
510 PROPERDIN IN NEISSERIAL INFECTIONS
of N. gonorrhoeae in properdin-depleted Mg/EGTA-NHS resulted
in small amounts of C3 deposited; addition of properdin to Mg/
EGTA-NHS augmented C3 deposition on all strains, minimally to
strain 15253 (Fig. 3B). N. gonorrhoeae strain F62 was chosen for
further studies because it bound the greatest amount of C3.
Because activity of the AP is concentration dependent (46), we
tested whether higher serum concentrations would permit optimal
AP activation in the absence of properdin. Shown in Fig. 4, in-
creasing the concentration of properdin-deﬁcient Mg/EGTA-NHS
to 80% resulted in no increase in the amount of C3 deposition at
30 min on two meningococcal strains tested, compared with sim-
ilar experiments in which 20% serum was used (Fig. 2B).
The presence of physiologic concentrations of properdin in
serum greatly enhanced C3 binding (Figs. 2B, 4). These results
show that properdin is required to boost AP activation on me-
ningococci even in the presence of high complement concen-
trations (as would be encountered by bacteria in the bloodstream).
Preincubation of Neisseriae with unfractionated properdin is
less efﬁcient in depositing C3 than serum reconstituted with
N. gonorrhoeae incubated with unfractionated properdin were
reported to show enhanced C3 deposition after addition of pro-
perdin-deﬁcient serum compared with diminished C3 deposition
FIGURE 3. P augments AP-mediated C3 deposition on N. gonorrhoeae. A, C3 deposition on ﬁve strains of N. gonorrhoeae incubated with NHS-Mg/
EGTA (20% [v/v]) alone (gray shaded histograms) or with added anti-properdin mAb (Quidel mAb A233) that blocks properdin function (histograms
depicted by solid lines). B. C3 deposition on gonococcal strains after incubation with P-depleted serum-Mg/EGTA (20% [v/v]) (histograms depicted by
solid lines) or with P-depleted serum-Mg/EGTA reconstituted with puriﬁed unfractionated P (gray shaded histograms). Numbers adjacent to histograms
represent the MFIs of C3 binding. Detection of C3 fragments was performed as in Fig. 1A. One representative experiment of two separately performed and
reproducibly repeated experiments is shown for each of the histograms.
FIGURE 4. P mediated deposition of C3 on Neisseriae at 80% serum concentration. Total C3 deposition on the unencapsulated derivatives of strains
A2594 and Y2220 incubated either with P-depleted serum-Mg/EGTA (ﬁnal concentration 80% [v/v]; solid black histograms) or P-depleted serum-Mg/
EGTA (ﬁnal concentration 80% [v/v]) reconstituted with puriﬁed unfractionated properdin (10 mg/ml; shaded gray histograms). Numbers adjacent to
histograms represent the MFIs of C3 binding. Detection of C3 was performed as in Fig. 1A. One representative experiment of two separately performed and
reproducibly repeated experiments is shown for each of the histograms.
The Journal of Immunology 511
on bacteria that were incubated with properdin-deﬁcient serum
Although these data suggested a role for bacteria-bound properdin
in ﬁxing C3 on gonococci, the relative balance between properdin
bound to bacteria directly versus properdin bound indirectly to
bacteria via C3bBb, which is necessary to maximally deposit C3,
was not determined. To address this, we compared C3 deposition
on Neisseriae that were handled as follows: 1) ﬁrst incubated with
unfractionated puriﬁed properdin, followed by the addition of pro-
perdin-depleted serum, or 2) incubated with properdin-depleted se-
rum that had been reconstituted with unfractionated properdin. The
unencapsulated mutant of A2594 and gonococcal strain F62 were
chosen because these strains bound the highest amounts of unfrac-
tionated properdin. Bacteria either were incubated with unfractio-
nated puriﬁed properdin (10 mg/ml in a ﬁnal volume of 100 ml),
washed once to remove unbound properdin, followed by the addi-
tion of properdin-depleted serum (ﬁnal concentration 20% [v/v]) or
were incubated in 20% properdin-depleted serum with unfractio-
nated properdin added to achieve a ﬁnal serum properdin concen-
tration of 10 mg/ml. The concentration of properdin in the reaction
mixture where bacteria had been preincubated with properdin
(10 mg/ml) was 5-fold higher than the ﬁnal concentration of pro-
perdin in the reaction mixture that contained 20% reconstituted
serum ([properdin] 2 mg/ml). Shown in Fig. 5, bacteria preincubated
with unfractionated properdin, followed by the addition of proper-
din-depleted serum bound less C3 than bacteria that were incubated
with properdin-sufﬁcient serum.
Neisseriae do not bind to native properdin
Unfractionated properdin contains high-order oligomers of proper-
din formed as a result of freeze thawing (35). Properdin in serum
contains only dimers, trimers, and tetramers (native properdin)
(2, 35). We hypothesized that an artiﬁcial increase in avidity
caused by high-order oligomerization and aggregation could result
in binding of properdin to surfaces that otherwise do not bind
the native forms of properdin. To explore this possibility on Neis-
seriae, properdin was fractionated by size exclusion chromatogra-
phy and properdin dimers, trimers, and tetramers (called P
, respectively) were tested for direct binding (in the absence
of C3 convertases) to Neisseriae by ﬂow cytometry. Properdin that
eluted in the void volume (higher-order oligomers, or P
commercially available unfractionated pure properdin were
used as controls.
Compared with unfractionated properdin, there was barely any
detectable binding of native properdin to any meningococcal or
gonococcal strains tested. Representative examples with N. men-
ingitidis strain A2594 (unencapsulated mutant) and N. gonor-
rhoeae strain F62, the strains that bound the highest amounts of
unfractionated properdin, are shown in Fig. 6A (left and middle
graphs). No binding was seen to P
only are shown for simplicity). In contrast, P
, and P
to a similar extent to zymosan (data with P
shown in Fig. 6A,
right graph). High amounts of P
and unfractionated properdin
bound to zymosan.
It was previously reported that binding of unfractionated pro-
perdin to E. coli K12 or Salmonella typhimurium strains increased
with LPS truncation [loss of the O-Ag, which contain repeating
saccharide structures (6, 47)]. Although unfractionated properdin
did not bind to wild-type enterobacterial strains that expressed the
O-Ag, mutants that expressed only the core oligosaccharide, or
that lacked part or all of the core oligosaccharide, bound well to
unfractionated properdin (6). Neisseria lack O-Ags and all Neis-
serial strains examined in this study, except gonococcal strain
15253, express 4–6 hexose residues extending outward from HepI
of the LOS core; the HepI of 15253 is substituted with a lactose
residue (48). To rule out the possibility that LOS hexose exten-
sions present in, for example, wild-type strain F62 may have
blocked binding of native properdin, we examined the binding
of properdin fractions to the LOS truncated lgtE (Glc→HepI)
and lgtF (Hep1 unsubstituted) mutants of F62. No binding of
any of the native forms of properdin to these mutants was ob-
served (data not shown). As expected, unfractionated properdin
bound well to the mutants with truncated LOS (not shown).
To determine whether serum components other than C3 con-
vertases could affect binding (either negatively or positively) of
properdin to Neisseriae, we measured properdin binding to bacteria
in the presence of C3-depleted serum. Properdin-depleted serum
served as a negative control and C3-depleted serum reconstituted
with C3 and NHS served as positive controls; all sera contained
Mg/EGTA to permit selective activation of the AP. No properdin
binding was measured on bacteria that were incubated with C3-
depleted serum (Fig. 6B, broken red histograms) and simulated
controls with properdin-depleted serum (Fig. 6B, green histo-
grams). Properdin binding was observed in sera that contained
both properdin and active C3 (NHS and reconstituted C3-
depleted serum, depicted by solid red and blue histograms in
Fig. 6B, respectively).
Preincubation of Neisseria with native forms of properdin does
not result in C3 deposition; native properdin augments C3
deposition by stabilizing C3 convertases
We assessed a downstream functional consequence of the in-
teraction of native properdin with Neisseria, which distinct from
unfractionated properdin, had not resulted in direct binding of
properdin to bacteria. We used native oligomers of properdin (2,
35) to conﬁrm its “conventional” role in promoting C3 deposition
on bacteria that result from secondary (or indirect) binding of
properdin to bacteria via C3b,Bb to stabilize AP C3 convertases.
FIGURE 5. Preincubation of Neisseriae with unfractionated P enhances
C3 deposition. Unencapsulated mutant of meningococcal strain A2594 and
N. gonorrhoeae strain F62 were incubated either with P-depleted serum-
Mg/EGTA (thin solid lines) or preincubated with unfractionated P (10 mg/
ml). Organisms were washed then P-depleted serum-Mg/EGTA (labeled
“Unfractionated P→P-depleted serum-Mg/EGTA”) was added (thick black
lines) or organisms were incubated with P-depleted serum-Mg/EGTA
reconstituted with unfractionated P (shaded gray histograms). Numbers
adjacent to histograms represent the MFIs of C3 binding. Detection of
C3 fragments was performed as in Fig. 1A. One representative experiment
of two separately performed and reproducibly repeated experiments is
shown for each of the histograms.
512 PROPERDIN IN NEISSERIAL INFECTIONS
Unencapsulated derivatives of strains A2594 and H44/76, encap-
sulated serogroup Y strain 2220, and gonococcal strain F62 were
preincubated with either P
, followed by the addition
of Mg-EGTA treated properdin-depleted serum. Controls included
bacteria plus properdin-depleted serum that was reconstituted with
each of the properdin fractions separately. Total C3 deposited on
bacteria was measured by ﬂow cytometry. Shown in Fig. 7, prein-
cubation of bacteria with P
did not enhance C3 binding
to any of the strains (shaded green histograms) compared with
properdin-deﬁcient serum alone (blue histograms). Preincubation
of meningococcal strains A2594 and H44/76 (both unencapsu-
lated), but not Y2220 (encapsulated) or F62, with P
enhanced C3 binding to bacteria (Fig. 7, shaded green histograms,
right column) compared with incubation with properdin-depleted
serum alone (solid blue histograms). In contrast, reconstitution of
properdin-depleted serum with each of the native fractions resulted
in an increase in C3 deposition on all strains (Fig. 7, solid red lines).
Collectively, these data indicate that the primary mechanism of
native properdin-mediated augmentation of C3 deposition on
Neisseria involves stabilization of C3 convertases. C3 deposition
seen when bacteria are preincubated with unfractionated properdin
is likely mediated by the high-order oligomers in the preparations
and may not reﬂect physiological conditions in vivo.
Ab-dependent bactericidal activity is important for protection
against meningococcal infection (49, 50). The AP plays an impor-
tant role in amplifying C3 deposition on the bacterial surface. C3
activation represents the convergence of the classical, lectin and
APs. The subsequent activation of the terminal complement com-
ponents can lead to C5b-9 insertion into the membrane of Gram-
negative pathogens, resulting in complement-dependent killing.
Deﬁciencies of the terminal complements (C5–C9) and AP com-
ponents, such as factor D and properdin, predispose individuals to
invasive meningococcal infections (11, 20, 51). Properdin deﬁ-
ciency is rare, but individuals with properdin deﬁciency are pre-
disposed to severe invasive meningococcal infections, often with
a higher mortality than normal individuals (11, 20, 51). Both
N. meningitidis and N. gonorrhoeae have evolved several intricate
mechanisms to evade complement. The previously reported ability
of N. gonorrhoeae to bind to properdin and activate complement
(6) would provide a distinct disadvantage to the bacteria in vivo.
Two important observations have emerged from this study. First,
properdin is critical for maximal AP-dependent C3 deposition on the
pathogenic Neisseriae, and second, native properdin does not bind
directly to any of the strains of N. meningitidis or N. gonorrhoeae
tested and does not initiate AP activation when preincubated with
Neisseriae. Together, these results strongly suggest that properdin
acts to enhance AP activation on Neisseriae through the “conven-
tional” mechanism, namely, by stabilizing AP C3 convertases.
These studies emphasize the importance of using native properdin
for functional assays. The only forms of properdin reported in
serum are dimers, trimers, and tetramers (P
tively) that are present in the ratio of 26:54:20 (2, 35). Higher-order
oligomers (aggregates of properdin) that form when properdin is
freeze thawed (as seen in commercial preparations), or with
FIGURE 6. Binding of fractionated P to Neisseriae. A, P was fractionated into dimers (P
), trimers (P
), tetramers (P
), and higher-order oligomers (P
properdin in the void volume of a size-exclusion chromatograph). Binding of each of these fractions to N. meningitidis A2594 (unencapsulated) and
N. gonorrhoeae F62 was measured by ﬂow cytometry. Binding of P
, and P
yielded nearly identical results; results with the P
fraction (only) are
shown for simplicity (solid green line). Binding of P
is shown by the red line; binding of commercially available unfractionated P by the blue line. B,
Serum P binds to Neisseriae in the presence of the alternative pathway of complement. P binding to unencapsulated N. meningitidis A2594 and N.
gonorrhoeae F62 after incubation with C3-depleted serum-Mg/EGTA (broken red histograms), P-depleted serum-Mg/EGTA (green histograms), C3-
depleted serum-Mg/EGTA reconstituted with puriﬁed C3 (solid red histograms), or normal human serum-Mg/EGTA (blue histograms). All sera contained
10 mM Mg
and 10 mM EGTA and the ﬁnal concentration of sera in all reaction mixtures was 20%. Axes are as described in Fig. 1. Controls (no added
serum) are shown by the black broken lines. Numbers adjacent to histograms represent the MFIs of P binding. One representative experiment of two
separately performed and reproducibly repeated experiments is shown for each of the histograms.
The Journal of Immunology 513
prolonged storage of native properdin, can promote ﬂuid phase
complement activation and consumption when added to serum (2,
35). Furthermore, a recent study shows that higher-order oligomers
can bind nonspeciﬁcally to live cell surfaces where they promote
complement activation (45).
There was a wide variation in C3 deposition among strains (Figs.
2, 3), which could reﬂect differences in the ability of strains to
activate the AP and/or availability of targets for C3 on the bac-
terial surface. An important observation was that expression of
groups A, B, C, and W-135, but not group Y, capsules all resulted
in less AP activation (shaded graphs in the upper panels of Fig.
2A,2B) as evidenced by less C3 deposition compared with their
isogenic unencapsulated mutants (gray shaded histograms in the
lower panels of Fig. 2A,2B). The mechanism of AP suppression
by select meningococcal capsular polysaccharides is currently the
subject of a separate investigation.
The importance of properdin in promoting AP activation on
Neisseriae was shown using a mAb against properdin that blocked
its function and resulted in a marked decrease in C3 deposition on
all meningococci and gonococci tested. These ﬁndings were
conﬁrmed by an independent method where C3 deposition on
Neisseriae was enhanced when properdin-depleted serum was
reconstituted either with native or unfractionated properdin.
It is noteworthy that preincubating N. gonorrhoeae strain F62
with the unfractionated commercial properdin preparation, fol-
lowed by the addition of properdin-depleted serum (Fig. 5, right
graph, “Unfractionated P → P-depleted serum-Mg/EGTA”)
resulted in increased levels of C3 deposition compared with
preincubation of strain F62 with P
(void volume eluate of
a molecular sieve column), shown in Fig. 7 (shaded green
histogram, lower right graph). This may be explained by lower
amounts of P
binding to F62 relative to unfractionated properdin
(Fig. 6A). High-order oligomers present in commercial properdin
preparations may have also been retained by the molecular sieve
column. Potentially, these retained aggregates in P
inﬂuenced binding to strain F62 and consequent C3 deposition that
simulated C3 binding brought on by unfractionated commercial
properdin. This may have also inﬂuenced higher C3 binding by
unencapsulated Group A and B N. meningitidis by the P
ration, which enhanced C3 deposition when added either before
FIGURE 7. Preincubation with native P does not enhance C3 deposition on Neisseriae. Unencapsulated derivatives of serogroup A strain 2594 and
serogroup B strain H44/76, encapsulated serogroup Y strain 2220 and gonococcal strain F62 were preincubated either with properdin dimers (P
), tetramers (P
) or higher-order oligomers (P
) each to a ﬁnal concentration of 10 mg/ml and washed. P-depleted serum-Mg/EGTA was then added to
a ﬁnal concentration of 20%. C3 deposition on bacteria was measured by ﬂow cytometry (shaded green histograms). Bacteria incubated only with
P-depleted serum-Mg/EGTA (ﬁnal concentration 20%) are shown by the blue histograms. C3 deposition was also measured on bacteria that were incubated
with P-depleted serum-Mg/EGTA that had been reconstituted with each of the puriﬁed properdin (P
, or higher-order oligomer [P
]) fractions (ﬁnal
concentration of each P fraction was 10 mg/ml; shown by the red histograms). Axes are as described in Fig. 1. Controls (serum lacking from the reaction
mixture) are indicated by the broken lines. Numbers adjacent to histograms represent the MFIs of P binding. One representative of two separately
performed and reproducibly repeated experiments is shown for each of the histograms.
514 PROPERDIN IN NEISSERIAL INFECTIONS
P-depleted serum-Mg/EGTA (Fig. 7, shaded green histogram in the
two upper graphs in the P
column) or together with P-depleted
serum-Mg/EGTA (Fig. 7, red histograms in the same graphs).
It is clear that certain complement activator surfaces, such as
zymosan, bind to puriﬁed native properdin (Fig. 6A). Other
complement activator surfaces, such as rabbit erythrocytes, have
also been reported to bind to commercially available unfractio-
nated properdin (6), although a recent study shows that the native
properdin forms do not (45). Studies that deﬁne ligands or func-
tions of properdin using unfractionated properdin that may contain
aggregates need to be interpreted with caution. In addition, other
molecules, such as serum amyloid P component, have been
reported to interfere with the ability of properdin to bind to sur-
faces (52) and may limit the ability of properdin to initiate com-
plement activation in the context of serum.
In conclusion, our results emphasize the importance of using
native forms of properdin to analyze the biological and functional
roles of this molecule. The “conventional” mechanism of pro-
perdin function, which is to bind to and stabilize AP C3 con-
vertases, remains the principal mechanism of function on the
surface of Neisseria. The lack of this essential mechanism may
explain why properdin-deﬁcient individuals are more susceptible
to meningococcal infections.
We thank Dr. Ulrich Vogel (Universita
rzburg, Germany) for providing
meningococcal strains and mutants used in this study, Dr. Daniel Stein for
providing the plasmid to make F62 lgtF, Dr. Asesh Banerjee for the plas-
mid to make F62 lgtE, and Staci Snyder and Connie Elliot for their ex-
cellent technical assistance.
M.K.P. is an ofﬁcer of and has a ﬁnancial interest in Complement Tech-
nology, Inc., a supplier of complement reagents.
1. Nolan, K. F., S. Kaluz, J. M. Higgins, D. Goundis, and K. B. Reid. 1992.
Characterization of the human properdin gene. Biochem. J. 287: 291–297.
2. Pangburn, M. K. 1989. Analysis of the natural polymeric forms of human pro-
perdin and their functions in complement activation. J. Immunol. 142: 202–207.
3. Smith, C. A., M. K. Pangburn, C. W. Vogel, and H. J. Mu
Molecular architecture of human properdin, a positive regulator of the alternative
pathway of complement. J. Biol. Chem. 259: 4582–4588.
4. Fearon, D. T., and K. F. Austen. 1975. Properdin: binding to C3b and stabili-
zation of the C3b-depen dent C3 convertase. J. Exp. Med. 142: 856–863.
5. Pillemer, L., L. Blum, I. H. Lepow, O. A. Ross, E. W. Todd, and A. C. Wardlaw.
1954. The properdin system and immunity. I. Demonstration and isolation of
a new serum protein, properdin, and its role in immune phenomena. Science 120:
6. Spitzer, D., L. M. Mitchell, J. P. Atkinson, and D. E. Hourcade. 2007. Properdin
can initiate complement activation by binding speciﬁc target surfaces and pro-
viding a platform for de novo convertase assembly. J. Immunol. 179: 2600–2608.
7. Hourcade, D. E. 2006. The role of properdin in the assembly of the alternative
pathway C3 convertases of complement. J. Biol. Chem. 281: 2128–2132.
8. Densen, P., J. M. Weiler, J. M. Grifﬁss, and L. G. Hoffmann. 1987. Familial
properdin deﬁciency and fatal meningococcemia. Correction of the bactericidal
defect by vaccination. N. Engl. J. Med. 316: 922–926.
9. Fijen, C. A., E. J. Kuijper, A. J. Hannema, A. G. Sjo
holm, and J. P. van Putten.
1989. Complement deﬁciencies in patients over ten years old with meningo-
coccal disease due to uncommon serogroups. [see comments] Lancet 2: 585–
10. Nielsen, H. E., C. Koch, P. Magnussen, and I. Lind. 1989. Complement deﬁ-
ciencies in selected groups of patients with meningococcal disease. Scand. J.
Infect. Dis. 21: 389–396.
11. Ross, S. C., and P. Densen. 1984. Complement deﬁciency states and infection:
epidemiology, pathogenesis and consequences of neisserial and other infections
in an immune deﬁciency. Medicine (Baltimore) 63: 243–273.
holm, A. G., J. H. Braconier, and C. So
m. 1982. Properdin deﬁciency
in a family with fulminant meningococcal infections. Clin. Exp. Immunol. 50:
13. Braconier, J. H., A. G. Sjo
holm, and C. So
m. 1983. Fulminant menin-
gococcal infections in a family with inherited deﬁciency of properdin. Scand. J.
Infect. Dis. 15: 339–345.
14. Nielsen, H. E., and C. Koch. 1987. Congenital properdin deﬁciency and me-
ningococcal infection. Clin. Immunol. Immunopathol. 44: 134–139.
15. Genel, F., F. Atlihan, N. Gulez, A. G. Sjo
holm, L. Skattum, and L. Truedsson.
2006. Properdin deﬁciency in a boy with fulminant meningococcal septic shock.
Acta Paediatr. 95: 1498–1500.
16. Cunliffe, N. A., N. Snowden, E. M. Dunbar, and M. R. Haeney. 1995. Recurrent
meningococcal septicae mia and properdin deﬁciency. J. Infect. 31: 67–68.
th, P. J., A. G. Sjo
holm, G. N. Fredrikson, G. Misiano, R. Scherz,
U. B. Schaad, B. Uhring-Lambert, G. Hauptmann, J. Westberg, M. Uhle
n, et al.
1999. Properdin deﬁciency in a large Swiss family: identiﬁcation of a stop codon
in the properdin gene, and association of menin gococcal disease with lack of the
IgG2 allotype marker G2m(n). Clin. Exp. Immunol. 118: 278–284.
18. Schlesinger, M., U. Mashal, J. Levy, and Z. Fishelson. 1993. Hereditary pro-
perdin deﬁciency in three families of Tunisian Jews. Acta Paediatr. 82: 744–747.
19. Schlesinger, M., Z. Nave, Y. Levy, P. E. Slater, and Z. Fishelson. 1990. Preva-
lence of hereditary properdin, C7 and C8 deﬁciencies in patients with menin-
gococcal infections. Clin. Exp. Immunol. 81: 423–427.
20. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with com-
plement deﬁciencies. Clin. Microbiol. Rev. 4: 359–395.
21. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway
revisited. J. Cell. Mol. Med. 12: 1074–1084.
22. Hourcade, D. E. 2008. Properdin and complement activation: a fresh perspective.
Curr. Drug Targets 9: 158–164.
23. Jarva, H., S. Ram, U. Vogel, A. M. Blom, and S. Meri. 2005. Binding of the
complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol.
24. Jarvis, G. A., and N. A. Vedros. 1987. Sialic acid of group B Neisseria men-
ingitidis regulates alternative complement pathway activation. Infect. Immun. 55:
25. Madico, G., J. Ngampasutadol, S. Gulati, U. Vogel, P. A. Rice, and S. Ram.
2007. Factor H binding and function in sialylated pathogenic neisseriae is
inﬂuenced by gonococcal, but not meningococcal, porin. J. Immunol. 178: 4489–
26. Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman,
C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram. 2006.
The meningococcal vaccine candidate GNA1870 binds the complement regu-
latory protein factor H and enhances serum resistance. J. Immunol. 177: 501–
27. Parsons, N. J., P. V. Patel, E. L. Tan, J. R. C. Andrade, C. A. Nairn, M. Goldner,
J. A. Cole, and H. Smith. 1988. Cytidine 59-monophospho-N-acetyl neuraminic
acid and a low molecular weight factor from human blood cells induce lipo-
polysaccharide alteration in gonococci when conferring resistance to killing by
human serum. Microb. Pathog. 5: 303–309.
28. Ram, S., M. Cullinane, A. M. Blom, S. Gulati, D. P. McQuillen, B. G. Monks,
C. O’Connell, R. Boden, C. Elkins, M. K. Pangburn, et al. 2001. Binding of C4b-
binding protein to porin: a molecular mechanism of serum resistance of Neisse-
ria gonorrhoeae. J. Exp. Med. 193: 281–295.
29. Ram, S., D. P. McQuillen, S. Gulati, C. Elkins, M. K. Pangburn, and P. A. Rice.
1998. Binding of complement factor H to loop 5 of porin protein 1A: a molecular
mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J. Exp.
Med. 188: 671–680.
30. Ram, S., A. K. Sharma, S. D. Simpson, S. Gulati, D. P. McQuillen,
M. K. Pangburn, and P. A. Rice. 1998. A novel sialic acid binding site on factor
H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med.
31. Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and
C. M. Tang. 2006. Functional signiﬁcance of factor H binding to Neisseria
meningitidis. J. Immunol. 176: 7566–7575.
32. Schneider, M. C., R. M. Exley, S. Ram, R. B. Sim, and C. M. Tang. 2007.
Interactions between Neisseria meningitidis and the compl ement system. Trends
Microbiol. 15: 233–240.
33. Schneider, M. C., B. E. Prosser, J. J. Caesar, E. Kugelberg, S. Li, Q. Zhang,
S. Quoraishi, J. E. Lovett, J. E. Deane, R. B. Sim, et al. 2009. Neisseria men-
ingitidis recruits factor H using protein mimicry of host carbohydrates. Nature
34. Vogel, U., and M. Frosch. 1999. Mechanisms of neisserial serum resistance. Mol.
Microbiol. 32: 1133–1139 .
35. Farries, T. C., J. T. Finch, P. J. Lachmann, and R. A. Harrison. 1987. Resolution
and analysis of ‘ native’ and ‘activated’ properdin.
Biochem. J. 243: 507–517.
36. Findlow, H., U. Vogel, J. E. Mueller, A. Curry, B. M. Njanpop-Lafourcade,
H. Claus, S. J. Gray, S. Yaro, Y. Traore
, L. Sangare
, et al. 2007. Three cases of
invasive meningococcal disease caused by a capsule null locus strain circulating
among healthy carriers in Burkina Faso. J. Infect. Dis. 195: 1071–1077.
37. Hoang, L. M., E. Thomas, S. Tyler, A. J. Pollard, G. Stephens, L. Gustafson,
A. McNabb, I. Pocock, R. Tsang, and R. Tan. 2005. Rapid and fatal meningo-
coccal disease due to a strain of Neisseria meningitidis containing the capsule
null locus. Clin. Infect. Dis. 40: e38–e42.
38. Stephens, D. S. 2009. Biology and pathogenesis of the evolutionarily successful,
obligate human bacterium Neisseria meningitidis. Vaccine 27(Suppl 2): B71–
39. Claus, H., M. C. Maiden, R. Maag, M. Frosch, and U. Vogel. 2002. Many carried
meningococci lack the genes required for capsule synthesis and transport. Mi-
crobiology 148: 1813–1819.
40. Deghmane, A. E., D. Giorgini, M. Larribe, J. M. Alonso, and M. K. Taha. 2002.
Down-regulation of pili and capsule of Neisseria meningitid is upon contact with
epithelial cells is mediated by CrgA regulatory protein. Mol. Microbiol. 43:
The Journal of Immunology 515
41. Hammerschmidt, S., A. Mu
ller, H. Sillmann, M. Mu
hlenhoff, R. Borrow , A. Fox,
J. van Putten, W. D. Zollinger, R. Gerardy-Schahn, and M. Frosch. 1996. Capsule
phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing
in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the
outbreak of meningococcal disease. Mol. Microbiol. 20: 1211–1220.
42. Vogel, U., H. Claus, G. Heinze, and M. Frosch. 1999. Role of lipopolysaccharide
sialylation in serum resistance of serogroup B and C meningococcal disease
isolates. Infect. Immun. 67: 954–957.
43. Ram, S., J. Ngampasutadol, A. D. Cox, A. M. Blom, L. A. Lewis, F. St Michael,
J. Stupak, S. Gulati, and P. A. Rice. 2007. Heptose I glycan substitutions on
Neisseria gonorrhoeae lipooligosaccharide inﬂuence C4b-binding protein bind-
ing and serum resistance. Infect. Immun. 75: 4071–4081.
44. O’Rear, L. D., and G. D. Ross. 2001. Isolation and puriﬁcation of C3 from
human plasma. Curr Protoc Immunol Chapter 13:Unit 13 13.3.
45. Ferreira, V. P., C. Cortes, and M. K. Pangburn. 2010. Native polymeric forms of
properdin selectively bind to targets and promote activation of the alternative
pathway of complement. Immunobiology DOI:10.1016/j.imbio.2010.02.002.
46. Schreiber, R. D., D. C. Morrison, E. R. Podack, and H. J. Mu
Bactericidal activity of the alternative complement pathway generated from 11
isolated plasma proteins. J. Exp. Med. 149: 870–882.
47. Heinrichs, D. E., J. A. Yethon, P. A. Amor, and C. Whitﬁeld. 1998. The assembly
system for the outer core portion of R1- and R4-type lipopolysaccharides of
Escherichia coli. The R1 core-speciﬁc beta-glucosyltransferase provides a novel
attachment site for O-polysaccharides. J. Biol. Chem. 273: 29497–29505.
48. Yamasaki, R., D. E. Kerwood, H. Schneider, K. P. Quinn, J. M. Grifﬁss, and
R. E. Mandrell. 1994. The structure of lipooligosaccharide produced by Neis-
seria gonorrhoeae, strain 15253, isolated from a patient with disseminated
infection. Evidence for a new glycosylation pathway of the gonococcal lip-
ooligosaccharide. J. Biol. Chem. 269: 30345–30351.
49. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human im-
munity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.
50. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human im-
munity to the meningococcus. II. Development of natural immunity. J. Exp. Med.
51. Figueroa, J., J. Andreoni, and P. Densen. 1993. Complement deﬁciency states
and meningococcal disease. Immunol. Res. 12: 295–311.
52. Mitchell, L., and D. Hourcade. 2008. Inhibition of properdin-directed comple-
ment activation by serum amyloid P component. Mol. Immunol. 45: 4103. DOI:
53. Schneider, H., J. M. Grifﬁss, G. D. Williams, and G. B. Pier. 1982. Immuno-
logical basis of serum resistance of Neisseria gonorrhoeae. J. Gen. Microbiol.
54. Densen, P., S. Gulati, and P. A. Rice . 1987. Speciﬁcity of antibodies against
Neisseria gonorrhoeae that stimulate neutrophil chemotaxis. Role of antibodies
directed against lipooligosaccharides. J. Clin. Invest. 80: 78–87.
55. Gulati, S., A. Cox, L. A. Lewis, F. S. Michael, J. Li, R. Boden, S. Ram, and
P. A. Rice. 2005. Enhanced factor H binding to sialylated Gonococci is restricted
to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications
for serum resistance and evidence for a bifunctional lipooligosaccharide sialyl-
transferase in Gonococci. Infect. Immun. 73: 7390–7397.
56. Rice, P. A., and D. L. Kasper. 1982. Characterization of serum resistance of
Neisseria gonorrhoeae that disseminate. Roles of blocking antibody and gono-
coccal outer membrane proteins. J. Clin. Invest. 70: 157–167.
516 PROPERDIN IN NEISSERIAL INFECTIONS